Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Accounting Standards Update and Change in Accounting Principle

The following tables present the amounts as reported, net revisions, and as revised amounts for the immaterial revisions to previously reported amounts which are which is shown in the following tables:

	For the Three Months Ended March 31, 2021
	As Reported	Revisions	As Revised
Series C convertible preferred stock	851,607	(5,287)	846,320
Additional paid-in capital	226,022,287	(3,309,376)	222,712,911
Net loss	(6,057,306)	(6,211)	(6,063,517)
Accumulated deficit	(110,162,769)	3,320,124	(106,842,645)
Total stockholders' equity	117,574,556	5,461	117,580,017

	For the Three Months Ended June 30, 2021
	As Reported	Revisions	As Revised
Series C convertible preferred stock	851,607	(5,287)	846,320
Additional paid-in capital	226,834,239	(3,309,376)	223,524,863
Net loss	(7,665,161)	(1,944)	(7,667,105)
Accumulated deficit	(117,827,930)	3,318,180	(114,509,750)
Total stockholders' equity	110,721,347	3,517	110,724,864

	For the Three Months Ended September 30, 2021
	As Reported	Revisions	As Revised
Series C convertible preferred stock	851,136	(5,816)	845,320
Additional paid-in capital	228,023,085	(3,308,847)	224,714,238
Net loss	(9,266,717)	(2,756)	(9,269,473)
Accumulated deficit	(127,094,647)	3,315,424	(123,779,223)
Total stockholders' equity	102,643,005	761	102,643,766

Schedule of Amounts as Reported, Net Correction Adjustments, and Corrected Amounts for Note Disclosures Affected by the Corrections

The following tables present the amounts as reported, revisions, and as revised amounts for note disclosures affected by the immaterial revisions for the years ended December 31, 2020 and 2019:

	Year ended December 31, 2020						Year ended December 31, 2019
	As Reported		Revisions		As Revised		As Reported		Revisions		As Revised
Federal NOL	$	19,665,840	$	(11,279,909)	$	8,385,931	$	16,812,626	$	(12,056,292)	$	4,756,334
State NOL	4,497,069		(3,697,061)		800,008		2,439,015		—		2,439,015
Research and development credits	2,099,921		(1,596,515)		503,406		1,350,305		(1,178,674)		171,631
Lease liability	172,674		—		172,674		242,234		—		242,234
Stock compensation and other	1,108,314		—		1,108,314		889,167		—		889,167
Deferred tax asset valuation allowance	(26,812,522)		16,573,485		(10,239,037)		(20,945,997)		13,234,966		(7,711,031)
Total deferred tax asset	731,296		—		731,296		787,350		—		787,350
Deferred tax liability (In process R&D)	(957,000)		—		(957,000)		(957,000)		—		(957,000)
Right-of-use asset	(183,318)		—		(183,318)		(239,372)		—		(239,372)
Total deferred tax liability	(1,140,318)		—		(1,140,318)		(1,196,372)		—		(1,196,372)
Net deferred tax liability	$	(409,022)	$	—	$	(409,022)	$	(409,022)	$	—	$	(409,022)